Separately, Independent Research set a €12.50 ($14.88) target price on MediGene and gave the company a neutral rating in a report on Wednesday, December 6th.
MediGene (ETR:MDG1) opened at €12.66 ($15.07) on Monday. MediGene has a twelve month low of €8.53 ($10.15) and a twelve month high of €15.24 ($18.14).
MediGene Company Profile
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase.
Receive News & Ratings for MediGene AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene AG and related companies with MarketBeat.com's FREE daily email newsletter.